中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物制剂研究中心
iRGD Conjugated TPGS Mediates Codelivery of Paclitaxel and Survivin shRNA for the Reversal of Lung Cancer Resistance

文献类型：期刊论文

作者Shen, Jianan1; Meng, Qingshuo1; Sui, Huiping1,2; Yin, Qi1; Zhang, Zhiwen1; Yu, Haijun1; Li, Yaping1
刊名MOLECULAR PHARMACEUTICS
出版日期2014-08
卷号11期号:8页码:2579-2591
关键词paclitaxel survivin shRNA TPGS lung cancer nanoparticles
ISSN号1543-8384
DOI10.1021/mp400576f
文献子类Article
英文摘要Multidrug resistance (MDR) is one of the major obstacles in tumor treatment. Herein, we reported an active targeting strategy with peptide-mediated nanoparticles deep into tumor parenchyma, which iRGD conjugated D-a-tocopheryl polyethylene glycol 1000 succinate (TPGS) mediated codelivery of paclitaxel (PTX) and survivin shRNA (shSur) for the reversal of lung cancer resistance. Pluronic P85-polyethyleneimine/TPGS complex nanoparticles incorporated with iRGD-TPGS conjugate codelivering PTX and shSur systems (iPTPNs) could induce effective cellular uptake, RNAi effects, and cytotoxicity on A549 and A549/T cells. In particular, iPTPNs showed superiority in biodistribution, survivin expression, tumor apoptosis, and antitumor efficacy by simultaneously exerting an enhanced permeability and retention (EPR) effect and iRGD mediated active targeting effects. iPTPNs significantly enhanced the accumulation of PTX and shSur, down-regulated survivin expression, and induced cell apoptosis in tumor tissue. The in vivo antitumor efficacy showed the tumor volume of iPTPNs group (10 mg/kg) was only 12.7% of the Taxol group. Therefore, the iRGD mediated PTX and shSur codelivery system could be a very powerful approach for the reversal and therapy of lung cancer resistance.
WOS关键词DRUG-DELIVERY SYSTEMS ; IN-VIVO EVALUATION ; CELL-DEATH ; MULTIDRUG-RESISTANCE ; BLOOD COMPONENTS ; GENE DELIVERY ; CO-DELIVERY ; NANOPARTICLES ; ANGIOGENESIS ; INTEGRINS
资助项目National Basic Research Program of China[2010CB934000] ; National Basic Research Program of China[2013CB932704] ; National Basic Research Program of China[2013CB932503] ; National Natural Science Foundation of China[81230029] ; National Natural Science Foundation of China[81102388] ; Shanghai Program[11 nm0505900]
WOS研究方向Research & Experimental Medicine ; Pharmacology & Pharmacy
语种英语
WOS记录号WOS:000339982900008
出版者AMER CHEMICAL SOC
源URL[http://119.78.100.183/handle/2S10ELR8/276967]  
专题药物制剂研究中心
通讯作者Li, Yaping
作者单位1.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China;
2.Shenyang Pharmaceut Univ, Sch Pharm, Shenyang 110016, Peoples R China
推荐引用方式
GB/T 7714		 Shen, Jianan,Meng, Qingshuo,Sui, Huiping,et al. iRGD Conjugated TPGS Mediates Codelivery of Paclitaxel and Survivin shRNA for the Reversal of Lung Cancer Resistance[J]. MOLECULAR PHARMACEUTICS,2014,11(8):2579-2591.
APA Shen, Jianan.,Meng, Qingshuo.,Sui, Huiping.,Yin, Qi.,Zhang, Zhiwen.,...&Li, Yaping.(2014).iRGD Conjugated TPGS Mediates Codelivery of Paclitaxel and Survivin shRNA for the Reversal of Lung Cancer Resistance.MOLECULAR PHARMACEUTICS,11(8),2579-2591.
MLA Shen, Jianan,et al."iRGD Conjugated TPGS Mediates Codelivery of Paclitaxel and Survivin shRNA for the Reversal of Lung Cancer Resistance".MOLECULAR PHARMACEUTICS 11.8(2014):2579-2591.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。